Evidence map›Paper›PMID 39776654›Full record

ArticleChemical science2025

Late-stage installation and functionalization of alkyl pyridiniums: a general HTE amenable strategy to access diverse aryl alanine containing macrocyclic peptides.

Ahmet Kekec, Lauren My-Linh Tran, Christopher W Plummer, Dipannita Kalyani

Abstract read
In one paragraph

Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahmet KekecDiscovery Chemistry, Merck & Co., Inc. Rahway New Jersey 07065 USA dipannita.kalyani@merck.com ahmet_kekec@merck.com.
Lauren My-Linh TranDiscovery Chemistry, Merck & Co., Inc. Rahway New Jersey 07065 USA dipannita.kalyani@merck.com ahmet_kekec@merck.com.ORCID https://orcid.org/0000-0001-7554-676X
Christopher W PlummerDiscovery Chemistry, Merck & Co., Inc. Rahway New Jersey 07065 USA dipannita.kalyani@merck.com ahmet_kekec@merck.com.
Dipannita KalyaniDiscovery Chemistry, Merck & Co., Inc. Rahway New Jersey 07065 USA dipannita.kalyani@merck.com ahmet_kekec@merck.com.ORCID https://orcid.org/0000-0003-4349-8016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This manuscript describes a strategy to readily access diverse aryl and homoaryl alanine-containing pharmaceutically relevant macrocyclic peptides. A two-step sequence involving the late-stage installation of the pyridinium functionality on macrocyclic peptides followed by reductive couplings was implemented. These transformations are amenable to microscale high-throughput experimentation (HTE) and enable rapid access to aryl alanine-containing macrocyclic peptides that would otherwise be inaccessible

Identifiers

PMID39776654
PMCPMC11701726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.